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ABSTRACT
Patient-reported outcomes (PROs) are a comparatively novel concept in medicine and in public health ser-
vices evaluation. It relies on the fact that medical technologies are not able to give all the information about 
the treatment or a medical condition. Some essential data can be obtained only from the patient.
Herewith, the PROs approach is presented in relation to amniotic membrane transplantation (AMT) which 
is applied to patients who have been treated at Varna Specialized Eye Hospital for different severe anterior 
ocular surface diseases (AOSDs). 
The aim of the study is to present the PROs approach and the created especially for the study Patient-Re-
ported Outcome Measures (PROMs) tool. Further on, we aim to summarize, analyze and discuss the PROs-
data of the study. 
MATERIALS AND METHODS: The presented PROs study enrolls 306 hospitalized patients diagnosed 
in seven cohorts and suitable for AMT for a period of seven years (2010-2016). It is a part of a wider research 
project. Demographic data and disease-related characteristics were collected in addition to the PROMs ques-
tionnaire. The PROMs instrument consists of 4 domains/questions, and the possible answers are arranged 
in ordinal scales. The first domain is Pain, and the possible answers are 5 (0 - none; 1 - sometimes low; 2 - 
always low; 3 - moderate to severe; 4 - always severe). The second domain is Photophobia, and the possible 
answers are 4 (0 - none; 1 - only at strong light; 2 - at daylight; 3 - at moderate light). The third domain is Se-
cretion and the possible answers are 4 (0 - none; 1 - watery; 2 - mucous secretion; 3 - purulent discharge). 
The fourth domain is Hyperemia and the possible answers following the Efron grading scale are 5 (grade 0 
- normal; grade 1 - trace; grade 2 - mild; grade 3 - moderate; grade 4 - severe).
RESULTS AND DISCUSSION: The AM treatment resulted in a significant reduction of the symptoms 
in all domains (p< 0.001). Regarding the Pain domain, in all the groups, over 60% of the patients report-
ed improvement. More than 90% of the patients with the most severe conditions like keratitis reported im-
provement. The reported and analyzed results indicate that AMT has a positive impact on all the PROs do-
mains – Pain, Photophobia, Secretion and Hyper-
emia, for every patient (p<0.001). This is a novel 
study for Bulgaria, which aims to measure the im-
pact of AMT on PROs among a large number of pa-
tients with severe AOSDs divided into seven cohorts 
for seven years. AMT proved to be a surgical method 
for treatment of chronic, recurrent AOSDs that im-
prove patients’ subjective well-being.
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INTRODUCTION 
Patient-reported outcomes (PROs) 
Medicine as a science and practice has changed 
tremendously during the last centuries but the hu-
man nature of the healing art has always been the 
care for the patient. In 1863, the legendary Florence 
Nightingale in her “Notes on Hospitals” (1) sum-
marized “seven elements”, which are essential while 
evaluating the success of the curative process. One 
of these criteria is if the patient is “recovered or re-
lieved” as a result of the hospital experience.  Dur-
ing the years the importance of the subjective crite-
ria in clinical medicine and in public health has in-
creased. In 2009, the US Food and Drug Administra-
tion (FDA) (2) recommended that PROs be used as a 
desirable endpoint  in the medical product develop-
ment. Even though innovative technologies allow the 
measuring of physical, physiological or biochemical 
data of the patient, they are not able to provide all the 
data about the treatment or the disease. Some essen-
tial data can be obtained only from the patient. 
May be the most famous definition of a “health 
outcome” is that of Donabedian (3) which states that 
a health outcome is the change of the current and the 
future health status of the patient that might be due 
to prior health care, including medication or surgery. 
FDA defines PROs as any report of the status of a pa-
tient’s health condition that comes directly from the 
patient, without an interpretation of the patient’s re-
sponse by a clinician or anyone else. The outcome 
can be measured in absolute terms (e.g. severity of 
a symptom, sign, or state of a disease) or as a change 
from a previous measure.
Patient-Reported Outcome Measures 
(PROMs) are tools and/or instruments used to re-
port PROs. Therefore, PROMs (i.e. a questionnaire 
plus the information and documentation that sup-
port its use) are a means to capture PROs data used 
to measure treatment benefit, risk in medical prod-
uct clinical trials or public health services evaluation. 
Amniotic membrane transplantation (AMT) 
is a surgical treatment, which could be successfully 
assessed by the application of PROMs. AMT is a sur-
gical approach to manage severe anterior ocular sur-
face diseases (AOSDs). AOSDs are related to a dam-
age of the anatomical and physiological features of 
eye structures - eyelids, tear film, conjunctiva, cornea 
and limbus. Disabilities associated with AOSDs very 
often create a vicious circle in which the individu-
al protective mechanisms are not able to compensate 
and some irreversible processes like squamous meta-
plasia, cicatrization and vascularization lead to poor 
quality of life, reduced visual acuity and blindness. 
On the other hand, prolongеd use of topical medica-
tions has its adverse effects related to the content of 
antibiotics, steroids аnd preservatives (4,5). In such 
cases, a mediator is needed, on one hand to protect 
the cornea, to be oxygen-permeable enough, while 
limiting the penetration and growth of toxic agents 
and for an anti-inflammatory effect, and on the oth-
er hand to stimulate the growth and differentiation 
of surface cells. Nowadays, an alternative option is 
called tissue engineering as a part of the regenerative 
medicine based on the concept of transplantation of 
exogenous and/or stimulation of endogenous factors 
and stem cells for the generation of organic substitu-
ents and improvement of tissue function. One of the 
most important components of bioengineering is the 
support matrix, a role which the amniotic membrane 
(AM) fulfills. Its qualities are close to the perfect ma-
trix (6-9). The first AMT was documented about 70 
years ago. Subsequently, AM was established as a 
standard for the reconstructive surgery of the ocular 
surface (10,11). Today AM is widely used for recon-
struction of the ocular surface as a treatment of se-
rious corneal diseases such as corneal persistent, re-
current defects, corneal ulcers with or without desce-
metocele and perforation (12-14), neurotrophic ulcer, 
microbial keratitis, band keratopathy (15), bullous 
keratopathy, after photorefractive keratotomy and 
LASIK, and chemical burns (16). It is used for ocu-
lar pemphigoid and the Stevens-Johnson syndrome 
(17-19). Other indications for AMT include recon-
struction of the ocular surface such as conjunctiva 
surgery with various changes as squamous neoplasia, 
pterygium, symblepharon, reconstructive surgery of 
the fornices, stem cells deficit of the limb simultane-
ously with stem cell transplant, etc. (20). It acts as a 
“dressing” in various corneal pathologies. The am-
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niotic membrane was recently used as a substrate for 
culturing limbal stem cells for transplantation. 
The indications for AMT are many but the re-
search reports and analysis on AMT and related 
PROMs are still scarce.  
The aim of the study is to present the PROs 
approach and the created especially for the study 
PROMs tool. Further on, we aim to summarize, ana-
lyze and discuss the PROs data of the study. 
MATERIALS AND METHODS
Settings and Sample
The presented PROs prospective study enrolls 
306 hospitalized patients diagnosed and grouped 
into 7 cohorts suitable for AMT. It is a part of a wid-
er research project on AMT. Demographic data and 
disease-related characteristics were collected in addi-
tion to the PROs questionnaire.
Methods
The PROMs instrument consists of 4 domains 
and the possible answers are put in ordinal scales. 
The first domain is Pain, and the possible answers 
are 4 (0 - none, 1 - sometimes mild; 2 - constantly 
mild; 3 - moderate to severe; 4 - constantly severe). 
The second domain is Photophobia, and the possi-
ble answers are 4 (0 - none, 1 - only at strong light; 
2 - at daylight; 3 - at moderate light). The third do-
main is Secretion and the possible answers are 4 (0 
- none, 1 - only tearing; 2 - mucous secretion; 3 - pu-
rulent discharge). The fourth domain is Hyperemia 
and the answers following the Efron grading scale 
are 5 (grade 0 - normal, grade 1 - trace; grade 2- mild; 
grade 3 - moderate; grade 4 - severe) (Table 1). Three 
time points measurement was done: pre-operatively 
(0 day), on the eighth day after surgery and on the 
25th day. Patients fill in the PROMs instrument to 
assess subjective symptoms at each visit.
Statistical Analysis
The data was analyzed with SPSS v.20. To mea-
sure the significance, ANOVA on RANKS test with 
Student-Newman-Keuls Method has been applied 
and p-value below 0.05% was considered statistical-
ly significant. 
RESULTS 
All patients were transplanted cryopreserved 
AM type of filler or a combination technique (type 
of filler and coating). The patients were divided into 
seven cohorts according to their diagnosis. Table 2 
Demographic data
1. Sex:     ☐ male        ☐ female                 2. Age: ……….…… years.
Clinical information
3. Diagnosis of the patient: …………………………………………………………………………




4.1. Pain:  0 – none; 1- sometimes mild;  
2 – constantly mild; 3 – moderate to severe;  
4 – constantly severe
4.2. Photophobia: 0 – none; 1 – only at strong 
light; 2 – at daylight; 3 – at moderate light;
4.3. Secretion: 0 – none; 1 – watery;  
2 – mucous secretion; 3 – purulent discharge
4.4. Hyperemia: 0 – normal; 1 – trace;  
2 – mild, 3 - moderate; 4 – severe; 
5. Type of transplantation according to the depth and type of the defect of the cornea:
☐  type – patch/onlay
☐  type – graft/inlay:               ☐  one-layered             ☐  two-layered             ☐  multilayered
☐  type – onlay on burning
Table 1. PROMs instrument for evaluation of the amniotic membrane application for anterior ocular surface 
reconstruction
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shows the distribution of patients according to their 
diagnosis.
Pain intensity is one of PROs, which 
determines the subjective quality of treatment. The 
results show that in the pre-operative period 75% 
of the patients experience moderate and constantly 
severe pain, while in the postoperative period the 
pain is significantly reduced as early as on the 8th day 
and persists until the 25th day (p<0.001) The results of 
the effect after transplantation of AM on the 25th day 
show a significant reduction (over 60%) of pain in all 
cohorts of patients (p<0.001). A maximum effect is 
observed in patients with postsurgical keratitis, with 
a reduction of pain with over 95%. Patients with virus 
keratitis follow them and then the cohort of patients 
with relapsed defects and those with neurotrophic 
ulcers (Figure 1). 
While assessing photophobia, which is the 
second most important subjective factor for the 
patients, we take into consideration the significant 
difference in the pre-operative and postoperative 
period (p <0.001). In the pre-operative period patients 
primarily complain of photophobia during daylight 
hours and in moderate illumination. Due to AMT on 
the 8th and 25th postoperative day they experience 
photophobia only in strong light. At the end of 
the studied period more than half of the patients 
reported absence of photophobia in the cohorts with 
postoperative keratitis - 83%, other diagnoses - 69%, 
bacterial keratitis - 67% and viral keratitis - 59%. In 
the other cohorts photophobia was reported only in 
strong light (recurrent and persistent corneal defects 
- 62%, injuries and burns - 58% and neurotrophic 
ulcers - 43%) (p<0.001).
Secretion is another sign with subjective 
reflection. The results show that there is a significant 
difference in the patients’ sensation in the pre-
operative and postoperative period (p<0.001), and 
between the sensation on the 8th and the 25th day 
after transplantation of AM (p<0.001). In the pre-
operative period, more than 60% of the patients 
Fig. 1. Pain intensity improvement related to AMT. 
Preoperative and postoperative assessment on the 8th and 
25th day: 0 - none, 1 – sometimes mild, 2 – constantly 




1. Corneal persistent, recurrent 
defects:
66









2. Postsurgical keratitis: 30
Postoperative dellen (after 
pterigium) 
2
Postoperative after LASIK 5
After PKP 5
Bullous keratopathy 18
3. Neurotrophic ulcers 38






After Тu conjunctivae 1




6. Bacterial keratitis 30
7. Viral keratitis: 51
Postherpetic 33
After adenoviral keratoconj 
unctivitis
18
Таble 2. Description of the sample according the diagnosis
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experience tearing and mucus, most affected in the 
cohort of bacterial keratitis. On the 8th day only 19% 
of all cohorts report such symptoms, and on the 25th 
day only 9% experience tearing or the symptom is 
missing. The bacterial keratitis cohort is the one 
affected the most in regard to this symptom. On the 
25th day there are patients from all cohorts who still 
have pyogenic secretion, 15% in the cohorts with 
injuries and burns, 6% in the cohorts with bacterial 
keratitis and in the other cohorts there are only a few 
cases (p<0.001).
Hyperemia (red eye) is the last of the PROs. A 
moderate and severe form of hyperemia in the pre-
operative period in more than 80% of the patients 
in all cohorts. A tendency towards reduction of the 
redness in the postoperative period on the 8th day 
after AMT is reported. For this short postoperative 
period a significant part of the patients had an 
average redness, more than 50% of the cohorts with 
postoperative keratitis and neurotrophic ulcers had 
mild redness (p<0.001). Severe redness occurs in only 
4% of the patients with burns and injuries and the 
patients with viral keratitis. A lack of redness was 
diagnosed in two cohorts - 21% in the cohort with 
recurrent or persistent corneal disorders and 20% 
of patients with viral keratitis. Moderate and severe 
redness was reported in only 6% of the patients on 
the 25th day (p<0.001).
All the reported and analyzed results indicate 
that AMT has a positive impact on all the PROs 
domains for every patient (p<0.001). This is the first 
study in our country, which aims to measure the 
impact of AMT on PROs among a large group of 
patients with different diagnosis over a seven-year 
period. 
DISCUSSION
The results of this study demonstrate the 
important role of PROs and PROMs in the 
assessment of AMT in severely damaged anterior 
ocular surface. If chronic and recurrent AOSDs are 
not treated, there will be long-term pathological 
consequences for the patients. The inflammatory 
process leads to symptoms either directly (such as 
pain) or more indirectly (such as emotional and 
social problems), and also to long-term anterior 
ocular surface damage and blindness, which itself 
leads to symptoms such as pain and to disability. 
Based on information gathered by filling out the card 
during the treatment, it was found that AMT has a 
strong effect on the subjective symptoms in patients 
with severe and chronically damaged ocular surface. 
The long period of research and the inclusion of 
patients with different diseases is a guarantee for 
representativeness and comparability of the results 
with those from the world practice of AMT. When 
treating eye surface diseases, pain relief is often a 
key outcome. However, pain cannot be quantified 
with objective clinical measures; PROMs are the 
only way to assess patients’ subjective experience. 
In 2014, Stefaniu et al. described the effectiveness of 
applying AM in bullous keratopathy resulting from 
pseudophakic, aphakic and transplant rejection. 
The results of the study showed a lack of bullae 
within 1-2 weeks after the transplantation, as well as 
absence of pain, photophobia and tearing. Despite 
the recurrence of symptoms after the resorption of 
AM, a positive influence on PROs was reported in 
88% of patients within a 4-year follow-up period 
(21). Srinivas et al. (2007) studied the effectiveness 
of AMT in regard to pain and additional indications 
in 7 patients (7 eyes) with bullous keratopathy and 
its role in reference to vision improvement in eyes 
with visual potential. The average follow-up period 
was 26.57 weeks. In 100% of the cases a full effect 
on pain was reported. In terms of the additional 
indicators: foreign body sensation, photophobia and 
tearing improvement were reported soon after the 
first postoperative day. An improvement in vision 
in 5 of the 7 patients (71.42%) was observed. The 
authors conclude that AMT is an effective alternative 
treatment of painful bullous keratopathy. Similar 
results in terms of pain were observed by other 
authors (22-24). In 2015, Tok et al. demonstrated in 
15 eyes of 10 patients with toxic keratopathy after 
application of a topical anesthetic that the initially 
conducted conservative treatment was not effective 
because of the intense pain, persistent epithelial 
defects and progressive stromal thinning. For that 
reason the authors performed AMT, which led to a 
significant improvement in all cases except for two. 
In another publication in 2015, Sui et al. studied 
21 eyes of 20 patients with bullous keratopathy 
and moderate pain was encountered pre- and 
postoperatively. They found that, postoperatively, 
76% of the eyes experienced absolutely no pain, 
Patient–Reported Outcomes – an Approach and Application in Amniotic Membrane Transplantation
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while others complained of mild pain and 47% of 
the eyes remained asymptomatic for 3.6 months. 
In 2003, Espana et al. describe that they overcame 
88% of the severe pain in the eyes with bullous 
keratopathy (25). These data suggest that AM plays 
an essential role in reducing the pain and the other 
subjective symptoms when the ocular surface has 
been damaged. In addition to the above-mentioned 
subjective indicators, AM plays a positive role on 
the inflammation processes and the hyperemia 
associated with them. The application of AM has a 
proven positive effect on the subjective sensation of 
redness (26). In 2005, Huang et al. showed that with 
patients with pterygium and AMT, the ocular surface 
recovers faster than in the cohort without AMT and 
both the levels of conjunctival hyperemia and the 
symptoms were lower (27). In 2016, Cheng et al. 
showed that the use of cryopreserved AM in patients 
with dry eye significantly affected the hyperemia 
for about 5 days and relieved the symptoms during 
the studied period which was four months (28). Our 
results based on PROs are in line with the published 
data, as we observed constant significant decrease of 
the redness upon AMT.
CONCLUSION
AMT proved to be a surgical method for 
treating severe anterior ocular surface disease that 
improves the patients’ subjective well-being. The 
heterogeneity in the disease presentation, analyzed 
for 7 years pre- and postoperatively further enforces 
the above-mentioned statement regarding the 
favorable outcome of AMT in the growing range 
of AOSDs. The authors, being clinicians and public 
health researchers, are strong supporters of PROs 
application due to its patient- or person-centered 
approach. PROs employment is an effective way to 
assess the result of any health intervention. PROs 
have been increasingly recognized as part of the 
holistic approach to health, a necessary ingredient to 
comprehensive assessment of the impact of treatment 
and care. Practically, the PROs approach is a real-life 
personalized medicine.
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